With the prevalence of diabetes continuing to grow in many countries, it is one of the most serious chronic health challenges we face today.
adults worldwide have diabetes.
Type 2 diabetes accounts for approximately
of all cases of diagnosed diabetes in adults.
Diabetes is the
leading cause of death in the U.S. and the eighth worldwide.
Diabetes is one of Merck’s top therapeutic priorities and a point of passion for many colleagues at Merck, both personally and professionally.
Karen, a Merck employee, shares her own experience living with type 2 diabetes.
LEADERSHIP THROUGH INNOVATION AND COLLABORATION
“Advancements in diabetes research are making a remarkable difference for patients, but there is much more work to be done. At Merck, we strive for scientific excellence and innovation in all stages of diabetes research, from discovery to rigorous research of medicines once approved. I am proud to be part of a research team that is committed to doing something truly meaningful to help people with diabetes.”
“Because diabetes is complex and a growing health challenge, we are committed to collaborating globally with other healthcare innovators, and mobilizing our own talent throughout the company, to advance the care of people living with diabetes.”
America's Diabetes Challenge: Get to Your Goals is a Merck-sponsored program created with the American Diabetes Association® and iHeart Media to raise awareness among people with type 2 diabetes about the importance of working with their doctors to set and reach their A1C goals. The program also aims to help people learn if they are at risk of low blood glucose and how to help reduce that risk.
In 2009, the Merck Foundation, a U.S.-based, private foundation, launched the Alliance to Reduce Disparities in Diabetes with a commitment of $15 million to address the growing problem of healthcare disparities related to type 2 diabetes in the U.S. among low-income and underserved adult populations.
An evaluation of programs within the Alliance to Reduce Disparities in Diabetes revealed that a new model of chronic disease management for vulnerable populations with diabetes shows significant promise.